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Abstract
Background: Lyme borreliosis, a potentially severe tick-borne infection caused by Borrelia burgdorferi, can cause
multi-system inflammatory disease. The incidence has been increasing, as has the number of patients with persistent
symptoms attributed to Borrelia. These symptoms, also referred to as post-Lyme disease syndrome, may follow an
erythema migrans or other Lyme manifestations, and include pain, fatigue, and cognitive disturbances. The optimal
duration of treatment for these symptoms is a subject of controversy. The PLEASE study is designed to determine
whether prolonged antibiotic treatment leads to better patient outcome than standard treatment.
Methods/Design: The PLEASE study is a double-blind, randomized, placebo-controlled trial. Based on power
analysis and compensating for possible loss to follow-up, a minimum of 255 patients with borreliosis-attributed
persistent symptoms are included. These symptoms are either (a) temporally related to an erythema migrans or
otherwise proven symptomatic borreliosis, or (b) accompanied by a positive B. burgdorferi IgG or IgM immunoblot. All
patients receive open-label ceftriaxone for two weeks. Patients are then randomized (ratio 1:1:1) to blinded oral follow-up
treatment for 12 weeks with (I) doxycycline, (II) clarithromycin combined with hydroxychloroquine, or (III) placebo.
The primary outcome is the physical component summary score (PCS) of the RAND-36 Health Status Inventory
(RAND SF-36) at week 14. Secondary outcomes include physical and mental aspects of health-related quality of
life (assessed by the subscales of the RAND SF-36), fatigue, neuropsychological evaluation, physical activity, and
cost-effectiveness.
Discussion: This article describes the background and design issues of the PLEASE study protocol. The results of
this study may provide evidence for prescribing or withholding prolonged antibiotic treatment.
Trial registration: ClinicalTrials.gov: NCT01207739, Netherlands Trial Register: NTR2469
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Background
Lyme borreliosis, the most common tick-borne infection
in America, Europe, and Northern Asia, is a multi-system
inflammatory disease caused by the spirochete Borrelia
burgdorferi sensu lato. During the past two decades, the
incidence has been increasing. In the USA, the number of
reported borreliosis cases has doubled from 9,908 cases in
1992 to 19,931 in 2006 [1]. Incidence rates vary per state
but have increased substantially over the last decade, with
an incidence up to 75 cases per 100,000 persons in 2012
[2]. In the Netherlands, the incidence of the most com-
mon form of borreliosis, erythema migrans (EM), has
risen from 39 per 100,000 in 1994 to 134 per 100,000 per-
sons in 2009 [3-5].
In parallel with the growing incidence of early Lyme dis-
ease, the number of patients with persistent symptoms at-
tributed to infection with B. burgdorferi seems to increase
as well. These borreliosis-attributed persistent symptoms,
also referred to as post-Lyme disease syndrome, chronic
Lyme disease, or (true or presumed) persistent Lyme dis-
ease, may follow an EM or other, possibly unnoticed, man-
ifestations of early Lyme disease, regardless of initial
appropriate antibiotic treatment. Patients mainly present
with pain, fatigue, neurological, and cognitive disturbances
[6-8]. Three months after treatment of an EM, the preva-
lence of these symptoms can be as high as 25% [9]. Al-
though this percentage tends to decrease as more time
elapses, symptoms are often disabling, and influence the
daily life of these patients. Especially chronic pain has
been shown to be an important contributor to impairment
of health-related quality of life, and is similar to that re-
ported by patients with osteoarthritis [10].
So far, no general, well-accepted definition of the syn-
drome of borreliosis-associated persistent symptoms
exists [11]. This has resulted in a lack of data on its inci-
dence and prevalence, and has contributed to confusion
and controversy. This controversy especially relates to the
pathogenesis of borreliosis-attributed persistent symp-
toms: whether they emerge from an ongoing infection, are
a post-infectious problem, or are not related to a Borrelia
infection at all. Currently available diagnostic tools (pri-
marily based on serology) are appropriate for the diagnosis
of early Lyme disease in most cases, but have little value
for the diagnosis of potentially persistent Borrelia infec-
tion [12]. As IgG antibodies against Borrelia may persist
for many months or even years after acute infection, posi-
tive serology is not an indicator of active or persistent Bor-
relia infection [13,14]. As long as there is no specific
laboratory test for active infection, the decision whether
and how long patients with persistent symptoms should
be treated depends on evidence from clinical studies.
However, as this evidence has not been consistent, two
different approaches exist for patients with borreliosis-
attributed persistent symptoms: (1) standard short-term
treatment for 2–4 weeks, as advised for most manifesta-
tions of Lyme borreliosis by the Infectious Diseases Soci-
ety of America (IDSA) [15] or (2) long-term treatment for
at least 3 months, as advised by the International Lyme
and Associated Diseases Society (ILADS) [16]. Previous
randomized clinical trials have not convincingly demon-
strated beneficial effects of prolonged antibiotic treatment
[10,17,18], and have been subject of ongoing debate [19].
To obtain more insight into the optimal treatment regi-
men for patients with borreliosis-attributed persistent
symptoms, we designed a double-blind, randomized clin-
ical trial to compare short- versus long-term treatment.
In this 3-arm study, entitled Persistent Lyme Empiric
Antibiotic Study Europe (PLEASE), ceftriaxone followed
by doxycycline (arm 1) or ceftriaxone followed by the
combination of clarithromycin and hydroxychloroquine
(arm 2) are compared to short-term therapy with ceftri-
axone followed by placebo (arm 3). Here, we describe the
study protocol.
Methods/Design
Study design
A randomized, double-blind, placebo-controlled trial is
performed to determine whether long-term antibiotic
treatment (ceftriaxone followed by doxycycline or cef-
triaxone followed by the combination of clarithromycin
and hydroxychloroquine) leads to better patient out-
come than short-term treatment (ceftriaxone followed
by placebo) in patients with borreliosis-attributed per-
sistent symptoms. This prospective 3-arm study is con-
ducted at two sites in the Netherlands, the Radboud
university medical center (Radboudumc) and the Sint
Maartenskliniek, and has been approved by the Medical
Ethics Review Committee CMO Regio Arnhem-Nijmegen
(registration number 2009/187, NL27344.091.09). The
study is conducted in accordance with the principles stated
in the most recent version of the Declaration of Helsinki
and the International Conference on Harmonisation (ICH)
guidelines on Good Clinical Practice.
Study population
All patients are recruited from the outpatient clinic of the
Radboudumc, after nationwide referral by physicians. The
Radboudumc serves as one of the tertiary referral centers
for the Netherlands’ population of around 17 million.
Screening is done using standard clinical and laboratory
protocols. Eligibility is assessed by a physician according
to specific inclusion and exclusion criteria (Table 1). In
short, patients with borreliosis-attributed persistent symp-
toms (musculoskeletal pain, arthritis, arthralgia, neuralgia,
sensory disturbances, or neuropsychological/cognitive
disorders, with or without persistent fatigue) are eli-
gible if these symptoms are either (a) temporally related
to an erythema migrans or otherwise proven symptomatic
Berende et al. BMC Infectious Diseases 2014, 14:543 Page 2 of 9
http://www.biomedcentral.com/1471-2334/14/543
borreliosis, or (b) accompanied by a positive B. burgdorferi
IgG or IgM immunoblot. An eligible patient is asked to
sign informed consent after obtaining written information
about the study.
Randomization and blinding
After obtaining informed consent and completing the
baseline assessment, patients are randomly assigned to
one of three groups in a 1:1:1 allocation ratio (Figure 1).
The randomization is computerized and balanced by
minimization for age (<or ≥40 years), gender, duration of
symptoms (<or ≥1 year), and baseline Global Health Com-
posite score of the RAND-36 Health Status Inventory
(RAND SF-36), consisting of all RAND SF-36 subscales
[22]. The randomization list consists of consecutive medi-
cation numbers that are entered into a secured web-based
database by an independent web manager. All personnel
involved in the study (except the web manager and study
pharmacist) and participants are masked to treatment al-
location. If the code is broken, it renders the patient non-
eligible. To assess success of masking, patients are asked
at the week 14 evaluation whether they think they have re-
ceived oral antibiotics or placebo.
Intervention
All patients are treated with open-label intravenous (i.v.)
ceftriaxone 2000 mg qd via a peripheral i.v. catheter for
14 days. To monitor side effects, patients are admitted
to the Sint Maartenskliniek for administration during
day 1 and 2. Subsequent doses, prepared by the Sint
Maartenskliniek Pharmacy, are given intravenously in a
home-care setting by specialized nurses. After comple-
tion of ceftriaxone treatment, patients start with the
randomized, blinded, oral study drugs. The oral drug
regimen comprises either (I) doxycycline 100 mg b.i.d.
combined with a placebo b.i.d. for 12 weeks, (II) clari-
thromycin 500 mg b.i.d. combined with hydroxychloro-
quine 200 mg b.i.d. for 12 weeks, or (III) double placebo
b.i.d. for 12 weeks. The study drugs are to be taken twice
daily after the meals. Study drugs and placebo are prepared
as capsules with identical appearance. Preparation and la-
beling of doxycycline, clarithromycin, hydroxychloroquine,
and placebo is performed by the Clinical Trials Unit of the
Department of Clinical Pharmacy of the Radboudumc
according to Good Manufacturing Practice (GMP) guide-
lines. Drug utilization is assessed by pill counting. Com-
pliance is verified by using patient diaries and MEMS
(Medication Event Monitoring System) caps [23,24].
Concomitant medication
Any antibacterial drugs other than study medications
are prohibited during the entire study period. In case of
proven intercurrent infections (e.g., urinary tract infec-
tion), specific antimicrobial therapy may be given for a
maximum of 5 days. Indications should be discussed
with the investigator, and efforts should be made to select
an antimicrobial drug with no in vitro activity against B.
burgdorferi. The following drugs are prohibited because of
potential interaction with study drugs or potential effects
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1 Males or non-pregnant, non-lactating females who are 18 years
or older
2 Complaints of musculoskeletal pain, arthritis, arthralgia, neuralgia,
sensory disturbances (such as paraesthesias or dysesthesias), or
neuropsychological/cognitive disorders, with or without persistent
fatigue, that are:
A either temporally related to an episode of erythema migrans or
otherwise proven symptomatic Lyme borreliosis (defined as within
4 months after erythema migrans as assessed by a physician, or
positive biopsy, PCR, culture, or intrathecal B. burgdorferi antibodies)
B or accompanied by a positive B. burgdorferi IgG or IgM immunoblot
(as defined by strict criteria in line with the European Union
Concerted Action on Lyme Borreliosis (EUCALB) and the
manufacturer of the immunoblot* [20,21]), regardless of prior ELISA
IgG/IgM screening results
3 Subjects must sign a written informed consent form
Exclusion criteria
1 Subjects with a known history of allergy or intolerance to
tetracyclines, macrolides, hydroxychloroquine, or ceftriaxone
2 Subjects who have had more than 5 days of antimicrobial therapy
with activity against B. burgdorferi within the previous 4 weeks
3 Subjects with a presumed diagnosis of neuroborreliosis (CSF
pleiocytosis or intrathecal antibody production) for which
intravenous antimicrobial therapy is required
4 Subjects with a known diagnosis of HIV-seropositivity or other
immune disorders
5 Subjects with positive syphilis serology or signs of other spirochetal
diseases
6 Subjects with moderate or severe liver disease defined as ALP, ALT,
or AST greater than 3 times upper limit of normal
7 Subjects who are receiving and cannot discontinue cisapride,
astemizole, terfenadine, barbiturates, phenytoin, or carbamazepine
8 Subjects who are currently enrolled on other investigational drug
trials or receiving investigational agents
9 Subjects who have been previously randomized into this study
10 Severe physical or psychiatric co-morbidity that interferes with
participation in the study protocol, including previous medical
diagnosis of rheumatic conditions, chronic fatigue syndrome, or
chronic pain conditions, as well as insufficient command of the
Dutch language
11 Co-morbidity that could (partially) account for the symptoms of
the subject (e.g., vitamin B12 deficiency, anemia, hypothyroidism)
12 Subjects of child-bearing potential unwilling to use contraception
methods other than oral contraceptives during the study therapy
period
Abbreviations: PCR = polymerase chain reaction, CSF = cerebrospinal fluid,
ALP = alkaline phosfatase, ALT = alanine aminotransferase,
AST = aspartate aminotransferase.
*EUROLINE-WB: Anti-Borrelia (whole antigen plus recombinant VlsE).
EUROIMMUN Corporation, Lübeck, Germany.
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on efficacy of treatment: cisapride, astemizole, terfena-
dine, barbiturates, phenytoin, carbamazepine, prednisone,
recombinant cytokines, hematopoietic growth factors,
or immunoglobulins. If treatment with one of these
drugs is required, the patient will be classified as ther-
apy discontinuation.
Assessments
An extensive baseline assessment is performed including
questionnaires, measurement of physical activity, and clin-
ical, laboratory, microbiological, and neuropsychological
evaluation. Neurological symptoms are assessed by the
lead study physicians using a standardized interview and
Screening
Randomizaon
Open-label i.v. ceriaxone (n=225; all paents)     
Arm II (n=75)
clarithromycin + 
hydroxychloroquine
Arm III (n=75) 
placebo
14 weeks aer start of treatment:
Efficacy evaluaon (primary endpoint)
26 weeks aer start of treatment:
Efficacy evaluaon (follow-up)
40 weeks aer start of treatment:
Efficacy evaluaon (end of study)
52 weeks aer start of treatment:
Efficacy evaluaon (post-study quesonnaires)
Eligibility + baseline assessment
Weeks in study
-2
0
0 -2
14
26
2 - 14
-2 - 0
40
52
Arm I (n=75)
doxycycline
Figure 1 Flowchart trial design.
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clinical neurological examination at baseline and week 14
[25].
Study visits for safety evaluation are performed at week
2, week 8, and week 14 after baseline. Safety assessments
include a medical history, physical examination, and la-
boratory investigation (hemoglobin, hematocrit, leukocytes,
platelets, glucose, creatinin, alkaline phosphatase, alanine
aminotransferase).
Efficacy evaluation is performed at week 14 (end of
treatment period, EOT), week 26 (12 weeks after EOT),
and week 40 after baseline (end of study, EOS, 26 weeks
after EOT). After the last comprehensive outcome as-
sessment at week 40, patients are surveyed by post-study
questionnaires at week 52.
Outcome measures
The primary outcome measure is health-related quality
of life at EOT (week 14), assessed by the physical com-
ponent summary score (PCS) of the RAND-36 Health
Status Inventory (RAND SF-36) [22]. This score is based
on the weighed subscale scores of the four physical
RAND SF-36 subscales (physical functioning, role limita-
tions due to physical health problems, pain, and general
health perceptions). The PCS is transformed to norm-
based T-scores (with a mean of 50 and a standard devi-
ation of 10 in the general population) and ranges from
15 to 61, with higher scores indicating a better physical
quality of life.
Main secondary endpoints include:
– (a) Physical and mental aspects of health-related
quality of life, assessed by the subscales of the
RAND SF-36 (physical functioning, role limitations
due to physical health problems, pain, general health
perceptions, emotional well-being (also known as
mental health), role limitations due to emotional
problems, social functioning, and energy/fatigue
(also known as vitality).
– (b) Fatigue, assessed by the Fatigue Severity subscale
of the Checklist Individual Strength (CIS) [26]. The
CIS is a reliable instrument with good validity and
sensitivity to change in patients with rheumatoid
arthritis, fibromyalgia, and chronic fatigue syndrome
[26-28].
– (c) Neuropsychological assessment covering the
five major cognitive domains, based on a similar
test battery previously used to measure borreliosis-
related impairment [7,29,30]. Episodic memory is
assessed using the Rey Auditory Verbal Learning
Test, using parallel versions for the follow-up
assessments to reduce nonspecific learning effects
[31]. Attention/Working memory is assessed using
the Digit Span test [32]. Language is measured
with the Category Fluency test (animal/profession
naming) [33]. Speed of information processing is
assessed using the Trail Making Test (TMT) part
A [34], the average speed of Cards I and II from
the Stroop Color-Word Test [35], and the Symbol-
Digit Substitution Test [36]. Executive functions are
measured using the TMT Interference score
(Part B/Part A) and the Stroop interference score
(Card III/average of Cards I and II) [37]. To
identify participants who display suboptimal effort
affecting symptom validity, the Amsterdam Short
Term Memory Test is administered at baseline
[38]. The entire test battery requires approximately
1 hour to be completed and is performed according
to a standardized protocol by three psychologists,
who have been trained in test administration and
scoring.
– (d) Physical activity during 12 days, measured by an
actometer. An actometer is a three-dimensional
motion device (43*29*16 mm) with a piezoelectric
sensor that is worn around the ankle [39]. Sensor
signals are stored every five minutes, from which
mean Daily Physical Activity scores are computed.
Actometers have been shown to yield valid and
highly reliable data [39,40].
Economic evaluation
To determine the cost-effectiveness of the different anti-
biotic regimens, an economic evaluation is conducted,
and these results will be published separately. This cost-
utility analysis investigates the potential efficiency of
short-term antibiotic therapy (2 weeks) versus long-term
antibiotic therapy (14 weeks) from a societal perspective.
Primary outcome measures are costs and quality-adjusted
life years (QALYs). For the overall quantification of health
status as a single index, the Dutch version of the standard
EQ-5D classification system developed by the EuroQol
Group is used [41]. QALYs will be estimated from the
EQ-5D scores over a one-year period using the trapez-
ium method.
The cost analysis consists of two main parts. First, vol-
umes of care are measured prospectively using a struc-
tured survey. Productivity losses for patients are estimated
using the Short Form - Health and Labour Question-
naire (SF-HLQ) [42,43]. The friction cost method will
be applied [44,45]. In the second part of the cost ana-
lysis, prices will be determined for each unit of care
consumed using the Dutch manual for cost research
[44]. The cost-effectiveness analysis will consist of com-
puting the incremental cost effectiveness ratio (ICER)
by dividing the mean difference in total costs by the
mean difference in QALYs. Insight into parameter un-
certainty will be obtained with the bootstrap method
and will be presented as cost-effectiveness acceptability
curves.
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Safety monitoring
Safety is evaluated by clinical laboratory tests and phys-
ical examinations. All observed and reported adverse
events, regardless of suspected causal relationship, are
recorded. An independent external data and safety moni-
toring board (DSMB) will review the blinded safety data
after the first 60 patients have reached the end of treat-
ment study visit. The DSMB may decide to recommend
study termination or protocol modifications if required by
the safety data or trial conduct.
Statistical analysis
Data will be analyzed according to the modified intention-
to-treat (mITT) principle. Patients who have been random-
ized into the study and received at least one dose of
ceftriaxone are included in the mITT analysis group.
In the primary analysis, analysis of covariance (ANCOVA)
will be used to compare the three study arms, with
gender and the baseline value of the dependent vari-
able as covariates. Pairwise comparisons are performed
for the different treatment modalities with Bonferroni
correction for multiple comparisons. Missing data will
be imputed by carrying the last observation forward,
in order to obtain a conservative estimate of the treat-
ment effect. No interim efficacy analysis will be per-
formed. Two-sided 5% significance levels will be used
to identify statistically significant results. All confi-
dence intervals reported will be 95% confidence inter-
vals. All statistical analyses will be performed using SPSS
software.
A sensitivity analysis will be performed on the per-
protocol subgroup. The per-protocol population com-
prises of patients for whom all of the following apply:
has met the in- and exclusion criteria; has taken at least
75% of the study drugs as recorded by MEMS; has not
taken any other antimicrobial drug for more than 5 days
during the study period; has not taken any prohibited
concomitant medication; has not been unblinded before
end of study.
When a difference between one of the experimental
treatments (ceftriaxone followed by 12 weeks of either
of the oral treatments) and the reference treatment
(two weeks ceftriaxone followed by placebo) is found,
subgroup analyses will be performed to identify factors
that may affect the treatment outcome. This will be
done by adding the factors and their interaction with
the treatment to the analysis of covariance model. The
duration of treatment effect will be evaluated in an ex-
plorative way with linear mixed models. When an out-
come variable is measured more than once, a random
(patient-dependent) intercept will be included in the
analysis.
To evaluate the neuropsychological outcomes, results
on individual tests will be standardized into z-scores to
make across-test comparison possible (using baseline
group mean and standard deviation as reference), and
averaged into cognitive domain scores. Higher z-scores
reflect a better performance. If necessary, scales will be
inverted, e.g., in the case of reaction times where higher
scores reflect a slower performance.
Sample size
The final power calculation was based on a pilot study
on 80 patients with borreliosis-attributed persistent
symptoms (Berende et al., unpublished). Patients were
classified as having a poor or reasonable clinical con-
dition as assessed during the first clinical consultation
at the outpatient clinic. The difference in the PCS score
between patients with a poor and those with a reason-
able clinical condition was 3 points, with a standard
deviation of 8. This corresponds with the minimally
clinically important difference (MCID) of 2 to 5 points
that has been proposed for the PCS [46]. In order to de-
tect a difference of 3 points with a power of 90%, a two-
sided alpha of 5% and a reliability coefficient (correlation
between consecutive measurements) of 0.7 [47], a mini-
mum of 75 patients are required per treatment group
(225 patients in total). To compensate for possible loss to
follow-up, a study population of at least 255 patients is
targeted for.
Discussion
The PLEASE study evaluates whether long-term anti-
biotic treatment of patients diagnosed with borreliosis-
attributed persistent symptoms is efficient and leads
to better patient outcome than short-term treatment.
So far, there are few prospective, controlled data to
support prolonged antibiotic treatment. Indeed, some
studies have suggested positive outcomes on selected
endpoints, such as persistent fatigue [17], cognitive
functioning [29], quality of life [18], or clinical response
rate [48], in specific groups of patients with putative
persistent Lyme disease. However, these results were
generally disappointing, and cannot be generalized.
Other randomized clinical trials have not demonstrated
beneficial effects of prolonged antibiotic treatment [10,30].
Importantly, all of these studies were performed in
North America. Borreliosis is caused by different Borrelia
species in the US and Europe, with different clinical
manifestations [49]. The present study will be the first
randomized clinical trial to study long-term antibiotic
treatment for borreliosis-attributed persistent symptoms
in Europe.
The strategic choices leading to the design of a pro-
spective, randomized, 3-arm study are complex. First, i.v.
ceftriaxone followed by doxycycline is generally consid-
ered the gold standard therapy for complicated borre-
liosis [10]. Whereas administration of ceftriaxone for
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longer than 2 weeks has been advocated, a randomized,
open-label study was unable to demonstrate that ceftri-
axone treatment for 4 weeks would be significantly bet-
ter [48].
Prolonged therapy with oral doxycycline has been asso-
ciated with success in a large case series of patients with
borreliosis-attributed persistent symptoms [50]. Data from
another case series suggested that combined therapy with
oral clarithromycin and hydroxychloroquine for at least 3
months may be at least as effective as prolonged doxycyc-
line [51]. Hydroxychloroquine increases the lysosomal pH
and is hypothesized to increase macrolide activity [52].
However, few conclusions can be drawn from those clin-
ical studies, as they were retrospective, uncontrolled, ob-
servational studies. Based on these considerations, the
present study was designed to compare a 12 weeks’ course
of doxycycline to 12 weeks of clarithromycin and hydroxy-
chloroquine versus placebo.
To provide a standard treatment for all patients, and to
cover potentially undiagnosed neuroborreliosis, all ran-
domized patients receive an open-label course of i.v. ceftri-
axone for 2 weeks preceding randomized blinded study
drugs. In this respect, the present study differs from
previous trials comparing prolonged therapy to placebo
[10,17,18,29]. By applying a standardized open-label
treatment to patients in all treatment arms, the study is
designed to compare short-term standard treatment
[15] to prolonged therapy as advocated by several pos-
ition papers [16,53]. In addition, this approach does not
leave potentially active infection untreated in patients
who are randomized to the control arm, and it also
controls for the wide variation in prior antibiotic ther-
apies (or lack thereof ) that patients with borreliosis-
attributed persistent symptoms may have received.
As the primary outcome measure, we have chosen the
physical component summary score (PCS) of the RAND-
36 Health Status Inventory (RAND SF-36) [22]. The
RAND SF-36 is similar to the Medical Outcomes Study
(MOS) 36-item Short-Form General Health Survey (SF-
36) [54]. The PCS, also known as the physical health com-
posite score (PHC) [22], is computed by a non-orthogonal
scoring algorithm. Several previous studies have used the
alternate (SF-36) version of the PCS, applying a principal
components analysis with orthogonal factors, with mental
health components contributing negatively to this PCS
score [54]. This SF-36 PCS has proven difficult to inter-
pret as the level of mental health influences the physical
health score and is therefore not purely a reflection of
physical health. Furthermore, the SF-36 PCS is less sensi-
tive to change than the underlying scales, while the RAND
SF-36 PCS has been shown to be sensitive to change
[55-62]. Despite the differences in calculation of both
composite scores, they do correlate highly, indicating that
they do represent similar constructs [58,59].
In conclusion, the PLEASE study is expected to pro-
vide evidence for prescribing or withholding prolonged
antibiotic treatment as compared to standard short-term
treatment in patients with borreliosis-attributed persist-
ent symptoms. In addition, this study may help to define
subgroups of patients who may or may not benefit from
additional antibiotic treatment, and contribute to a more
cost-effective management of this disease entity.
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